By C. Roy. Lewis & Clark College.
Active-control trial: A trial comparing a drug in a particular class or group with a drug outside of that class or group 3mg ivermectin with amex. Allocation concealment: The process by which the person determining randomization is blinded to a study participant’s group allocation ivermectin 3mg. Applicability: see External Validity Before-after study: A type nonrandomized study where data are collected before and after patients receive an intervention. Before-after studies can have a single arm or can include a control group. Bias: A systematic error or deviation in results or inferences from the truth. Several types of bias can appear in published trials, including selection bias, performance bias, detection bias, and reporting bias. Bioequivalence: Drug products that contain the same compound in the same amount that meet current official standards, that, when administered to the same person in the same dosage regimen result in equivalent concentrations of drug in blood and tissue. Black box warning: A type of warning that appears on the package insert for prescription drugs that may cause serious adverse effects. It is so named for the black border that usually surrounds the text of the warning. A black box warning means that medical studies indicate that the drug carries a significant risk of serious or even life-threatening adverse effects. The US Food and Drug Administration (FDA) can require a pharmaceutical company to place a black box warning on the labeling of a prescription drug, or in literature describing it. Blinding: A way of making sure that the people involved in a research study — participants, clinicians, or researchers —do not know which participants are assigned to each study group. Blinding usually is used in research studies that compare two or more types of treatment for an illness. Newer antiplatelet agents 64 of 98 Final Update 2 Report Drug Effectiveness Review Project Case series: A study reporting observations on a series of patients receiving the same intervention with no control group. Case study: A study reporting observations on a single patient. Case-control study: A study that compares people with a specific disease or outcome of interest (cases) to people from the same population without that disease or outcome (controls). Clinical diversity: Differences between studies in key characteristics of the participants, interventions or outcome measures. Clinically significant: A result that is large enough to affect a patient’s disease state in a manner that is noticeable to the patient and/or a caregiver. Cohort study: An observational study in which a defined group of people (the cohort) is followed over time and compared with a group of people who were exposed or not exposed to a particular intervention or other factor of interest. A prospective cohort study assembles participants and follows them into the future. A retrospective cohort study identifies subjects from past records and follows them from the time of those records to the present. Combination Therapy: The use of two or more therapies and especially drugs to treat a disease or condition. Confidence interval: The range of values calculated from the data such that there is a level of confidence, or certainty, that it contains the true value. The 95% confidence interval is generally used in Drug Effectiveness Review Project reports. If the report were hypothetically repeated on a collection of 100 random samples of studies, the resulting 95% confidence intervals would include the true population value 95% of the time. Confounder: A factor that is associated with both an intervention and an outcome of interest. Controlled clinical trial: A clinical trial that includes a control group but no or inadequate methods of randomization. Control group: In a research study, the group of people who do not receive the treatment being tested. The control group might receive a placebo, a different treatment for the disease, or no treatment at all. Convenience sample: A group of individuals being studied because they are conveniently accessible in some way. Convenience samples may or may not be representative of a population that would normally be receiving an intervention. Crossover trial: A type of clinical trial comparing two or more interventions in which the participants, upon completion of the course of one treatment, are switched to another. Direct analysis: The practice of using data from head-to-head trials to draw conclusions about the comparative effectiveness of drugs within a class or group. Results of direct analysis are the preferred source of data in Drug Effectiveness Review Project reports. Dosage form: The physical form of a dose of medication, such as a capsule, injection, or liquid. The route of administration is dependent on the dosage form of a given drug. Various dosage forms may exist for the same compound, since different medical conditions may warrant different routes of administration.
Rosiglitazone taken once daily provides effective glycaemic control in patients with Type 2 diabetes mellitus purchase ivermectin 3mg visa. Glycemic control with glyburide/metformin tablets in combination with rosiglitazone in patients with type 2 diabetes: a randomized order ivermectin 3 mg on line, double-blind trial. Rosiglitazone improves myocardial glucose uptake in patients with type 2 diabetes and coronary artery disease: a 16-week randomized, double-blind, placebo-controlled study. Negro R, Mangieri T, Dazzi D, Pezzarossa A, Hassan H. Rosiglitazone effects on blood pressure and metabolic parameters in nondipper diabetic patients. Effect of rosiglitazone on restenosis after coronary stenting in patients with type 2 diabetes. Pioneer study: PPARgamma activation results in overall improvement of clinical and metabolic markers associated with insulin resistance independent of long-term glucose control. Effect of early addition of rosiglitazone to sulphonylurea therapy in older type 2 diabetes patients (>60 years): the Rosiglitazone Early vs. Thiazolidinediones Page 99 of 193 Final Report Update 1 Drug Effectiveness Review Project 111. Impact of rosiglitazone on beta-cell function, insulin resistance, and adiponectin concentrations: results from a double-blind oral combination study with glimepiride. Effects of rosiglitazone maleate when added to a sulfonylurea regimen in patients with type 2 diabetes mellitus and mild to moderate renal impairment: a post hoc analysis. Rosiglitazone in Type 2 diabetes mellitus: an evaluation in British Indo-Asian patients. Effect of metformin and rosiglitazone combination therapy in patients with type 2 diabetes mellitus: a randomized controlled trial. Gomez-Perez FJ, Fanghanel-Salmon G, Antonio Barbosa J, et al. Efficacy and safety of rosiglitazone plus metformin in Mexicans with type 2 diabetes. Rosiglitazone but not metformin enhances insulin- and exercise-stimulated skeletal muscle glucose uptake in patients with newly diagnosed type 2 diabetes. Effects of metformin and rosiglitazone monotherapy on insulin-mediated hepatic glucose uptake and their relation to visceral fat in type 2 diabetes. Addition of rosiglitazone to metformin is most effective in obese, insulin-resistant patients with type 2 diabetes. Predictive clinical parameters for therapeutic efficacy of rosiglitazone in Korean type 2 diabetes mellitus. Lebovitz HE, Dole JF, Patwardhan R, Rappaport EB, Freed MI, Rosiglitazone Clinical Trials Study Group. Rosiglitazone monotherapy is effective in patients with type 2 diabetes. Effect of rosiglitazone on glucose and non- esterified fatty acid metabolism in Type II diabetic patients. Vascular effects of improving metabolic control with metformin or rosiglitazone in type 2 diabetes. Rosiglitazone monotherapy improves glycaemic control in patients with type 2 diabetes: a twelve-week, randomized, placebo-controlled study. Phillips LS, Grunberger G, Miller E, Patwardhan R, Rappaport EB, Salzman A. Once- and twice-daily dosing with rosiglitazone improves glycemic control in patients with type 2 diabetes. Raskin P, Rendell M, Riddle MC, Dole JF, Freed MI, Rosenstock J. A randomized trial of rosiglitazone therapy in patients with inadequately controlled insulin-treated type 2 diabetes. Thiazolidinediones Page 100 of 193 Final Report Update 1 Drug Effectiveness Review Project 126. Rosiglitazone amplifies the benefits of lifestyle intervention measures in long-standing type 2 diabetes mellitus. The effects of rosiglitazone on fatty acid and triglyceride metabolism in type 2 diabetes. Rosiglitazone improves postprandial triglyceride and free fatty acid metabolism in type 2 diabetes. Differential effects of rosiglitazone and metformin on adipose tissue distribution and glucose uptake in type 2 diabetic subjects.
Israel E ivermectin 3 mg overnight delivery, Banerjee TR cheap ivermectin 3 mg with mastercard, Fitzmaurice GM, Kotlov TV, LaHive K, LeBoff MS. Effects of inhaled glucocorticoids on bone density in premenopausal women. Johannes CB, Schneider GA, Dube TJ, Alfredson TD, Davis KJ, Walker AM. The risk of nonvertebral fracture related to inhaled corticosteroid exposure among adults with chronic respiratory disease. Use of inhaled corticosteroids and risk of fractures. Bone mineral density in children with asthma receiving long- term treatment with inhaled budesonide. Posterior subcapsular cataracts, bruises and hoarseness in children with asthma receiving long-term treatment with inhaled budesonide. Use of inhaled corticosteroids and the risk of cataracts. Association of inhaled corticosteroid use with cataract extraction in elderly patients. The risk of cataract among users of inhaled steroids. A population based case-control study of cataract and inhaled corticosteroids. Controller medications for asthma 206 of 369 Final Update 1 Report Drug Effectiveness Review Project 268. Inhaled corticosteroids, family history, and risk of glaucoma. Effect of long-term corticosteroid use on bone mineral density in children: a prospective longitudinal assessment in the childhood Asthma Management Program (CAMP) study. Hansen RA, Gartlehner G, Lohr KN, Carson S, Carey T. Macdessi JS, Randell TL, Donaghue KC, Ambler GR, van Asperen PP, Mellis CM. Adrenal crises in children treated with high-dose inhaled corticosteroids for asthma. Hypoglycemia due to adrenal suppression secondary to high-dose nebulized corticosteroid. Todd GRG, Acerini CL, Ross-Russell R, Zahra S, Warner JT, McCance D. Survey of adrenal crisis associated with inhaled corticosteroids in the United Kingdom. Nelson HS, Weiss ST, Bleecker ER, Yancey SW, Dorinsky PM. The Salmeterol Multicenter Asthma Research Trial: a comparison of usual pharmacotherapy for asthma or usual pharmacotherapy plus salmeterol. FDA Drug Safety Communication: Drug labels now contain updated recommendations on the appropriate use of long-acting inhaled asthma medications called Long-Acting Beta-Agonists (LABAs). Regular treatment with formoterol versus regular treatment with salmeterol for chronic asthma: serious adverse events. Regular treatment with formoterol and an inhaled corticosteroid versus regular treatment with salmeterol and an inhaled corticosteroid for chronic asthma: serious adverse events. Meta-analysis: effect of long- acting beta-agonists on severe asthma exacerbations and asthma-related deaths. Long-acting beta2-agonists for chronic asthma in adults and children where background therapy contains varied or no inhaled corticosteroid. Long-acting beta2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Controller medications for asthma 207 of 369 Final Update 1 Report Drug Effectiveness Review Project 285. Addition of inhaled long-acting beta2- agonists to inhaled steroids as first line therapy for persistent asthma in steroid-naive adults. Regular treatment with salmeterol for chronic asthma: serious adverse events. Post-inhalation bronchoconstriction by beclomethasone dipropionate: a comparison of two different CFC propellant formulations in asthmatics. Fluticasone propionate/salmeterol combination in children with asthma: Key cardiac and overall safety results. Adding omalizumab to the therapy of adolescents with persistent uncontrolled moderate--severe allergic asthma. Peters-Golden M, Swern A, Bird SS, Hustad CM, Grant E, Edelman JM. Influence of body mass index on the response to asthma controller agents. Smoking affects response to inhaled corticosteroids or leukotriene receptor antagonists in asthma.
Here it follows a tor- is an end-artery so that occlusion causes immediate blindness discount 3mg ivermectin visa. Other tuous course at the side of the mouth and lateral to the nose to reach the branches are described on p purchase ivermectin 3mg line. It gives off a tonsillar branch in the neck, superior and callosum and supplies the front and medial surfaces of the cerebral inferior labial branches and nasal branches. It anastomoses with its fellow of the opposite side. It is dis- • The posterior communicating artery: a small artery which passes tributed to the side of the scalp and the forehead. It ends by entering the pterygopala- These arteries and the communications between them form the tine fossa through the pterygomaxillary ﬁssure. Its principal branches Circle of Willis so that there is (usually) free communication between are to the local muscles including the deep temporal arteries to tem- the branches of the two internal carotid arteries across the midline. The arteries I 133 60 The arteries II and the veins C6 Subclavian artery Inferior Costocervical thyroid artery trunk Vertebral artery Scalenus anterior First rib Thyrocervical trunk Superior Costocervical intercostal artery trunk Dorsal scapular (usually) Apex of lung Axillary artery Subclavian artery First rib Fig. It arches across the upper surface of the 1st rib to • The inferior sagittal sinus: begins near the origin of the superior become the axillary artery. It is in close contact with the apex of the sagittal sinus and runs in the free border of the falx cerebri. It is joined lung and lies behind scalenus anterior at the root of the neck. The straight sinus • The internal thoracic artery: see p. The latter leaves the skull through the left jugular foramen. It passes through corresponding • The cavernous sinus: this lies at the side of the pituitary fossa and foramina in the other cervical vertebra to reach the upper surface of the contains the internal carotid artery. Here it turns medially in a groove and then enters the cranial cav- ophthalmic veins and is connected to some smaller sinusesathe super- ity through the foramen magnum. Here it joins its fellow of the opposite ior and inferior petrosal sinuses and the sphenoidal sinus. It gives off the anterior and posterior cavernous sinuses are joined in front and behind the pituitary by the spinal arteries which descend to supply the spinal cord, and the poster- intercavernous sinuses. The basilar artery passes forwards on the under- • The internal jugular vein: passes down the neck from the jugular surface of the medulla and pons and gives the anterior inferior cerebel- foramen, in the carotid sheath along with the internal and common lar artery, branches to the brainstem and to the inner ear (the internal carotid arteries and the vagus nerve. It ends by joining the subclavian auditory artery) and ends by dividing into the superior cerebellar and vein to form the brachiocephalic vein. It receives veins corresponding posterior cerebral arteries. The latter is joined by the posterior com- to the branches of the external carotid artery ( facial, lingual, pharyn- municating artery (p. The inferior thyroid • The costocervical trunk: a small artery that passes backwards to veins pass downwards in front of the trachea to open into the left bra- supply muscles of the back. It also supplies the superior thoracic artery chiocephalic vein. The facial vein communicates around the orbit with tributaries of the • The thyrocervical trunk: gives off the superﬁcial cervical and ophthalmic veins so that infections of the face may spread to the cav- suprascapular arteries and then passes medially as the inferior thyroid ernous sinus if not properly treated. It has a variable relation to the recurrent laryngeal of the retromandibular vein with other small veins. It passes obliquely nerve, lying in front or behind them, but may branch early with the across sternomastoid to open into the subclavian vein. It descends along the medial border of the scapula but may • The anterior jugular vein: begins below the chin and runs down the arise in common with the superﬁcial cervical artery. It then passes deep to sternomastoid to join the external jugular vein. The veins • The subclavian vein: lies in a groove on the 1st rib but is separated The veins of the brain drain into dural venous sinuses (Fig. The from the subclavian artery by the scalenus anterior. It receives the most important of these are: external jugular vein, veins corresponding to the branches of the sub- • The superior sagittal sinus: passes backwards in the midline in the clavian artery and, at its junction with the internal jugular vein, the thor- attached border of the falx cerebri from just above the cribriform plate acic duct on the left and the right lymph duct on the right. It then transversarium from the vertebral plexus of veins that accompany the winds down on the back of the petrous temporal as the sigmoid sinus vertebral artery. The arteries II and the veins 135 61 Anterior and posterior triangles Pretracheal fascia Investing layer of deep fascia Sternomastoid Common carotid artery Internal jugular vein Vagus nerve Prevertebral fascia Skin and superficial fascia Trapezius Fig. Trachea The arrows indicate the posterior triangle Pretracheal fascia Sternomastoid External jugular Thyroid Carotid sheath Vagus Thoracic duct Sympathetic trunk Longus colli Scalenus anterior Spinal nerve Long thoracic nerve Plane of accessory nerve Prevertebral Scalenus medius fascia Levator scapulae Splenius Trapezius Semispinalis Vertebral artery Fig. There are still some structures omitted from the diagram for the sake of simplicity, for example the strap muscles Greater auricular Anterior belly of digastric Lesser occipital Parotid Digastric triangle Semispinalis Posterior belly of digastric External jugular Splenius capitis vein Trapezius Transverse Levator scapulae cutaneous Accessory nerve Supraclavicular nerves Scalenus medius Hyoid bone Anterior jugular Submental Brachial plexus vein triangle Carotid (upper trunk) Omohyoid Omohyoid triangle Scalenus anterior Muscular triangle Fig. These are as follows: ous, without interruption, from one triangle to another so that it is more 1 The cervical vertebrae surrounded by a number of muscles and convenient to describe them individually in other chapters.
Even short-term lapses can have irreversible consequences cheap ivermectin 3mg overnight delivery. And every new occurrence of resistance complicates therapy buy 3 mg ivermectin amex. Such conversations should be repeated from time to time and become a standard component of routine care. Cooperation with special treatment discussion groups offered by patient-centered support organizations can be useful. The 12-step table below provides additional sug- gestions. In addition, a number of strategies on improving adherence have been investigated. They range from employment of additional nurses and patient com- munity to telephoning patients regularly (Review: Kenya 2011). The effect of these strategies, however, depends on the individual setting of the patient (Collier 2005, Chung 2011, Pop-Eleches 2011). If adherence remains poor Despite all efforts, some patients will not succeed in improving their adherence. Physicians and other healthcare providers should not take this personally or feel offended. Although it may be difficult to accept the patient’s views on life, disease and treatment, healthcare providers must keep tolerance and acceptance as key com- ponents in their interactions with patients. Some providers, especially those who treat selective patient populations in university settings, tend to forget the reality of routine medical practice. Rigidly upholding the principles of modern medicine usually does not help here and putting patients under pressure achieves even less. It is important to clearly outline and explain, advise, help, question and listen. The question of whether noncompliant patients should continue to be treated with antiretroviral therapy is not always easy to address. On the one hand, there are patients who benefit even from suboptimal therapy; on the other hand, drugs are expensive and should not be prescribed too readily. Restraint should be applied until the reason for poor compliance is understood. Duesbergians – a sect Patients who refuse antiretroviral treatment on principle are a special case. These patients are frequently not on treatment thanks to (shockingly misdirected) doctors, who call themselves “Duesbergians” (after the US virologist and AIDS dissident Peter Duesberg, who denies any association between AIDS and illness). In such cases, it can be very difficult to leave patients to their fate. Informative consultations should be as detailed as possible and preferably documented in writing. What to start with 181 Twelve steps to improve compliance • Every patient should receive a written (comprehensible) treatment plan, which should be reviewed at the end of the visit. It should include a telephone number to call (or email address) in case of problems or questions. The patient’s concerns, questions and criticisms should be discussed. It makes sense to repeat such conversations – they should not only take place when initiating or modifying treatment, but should be part of routine care. An example: An approximately 40-year-old patient with a long history of untreated HIV, 30 CD4 T cells/µl and cerebral toxoplasmosis (TE), which improved significantly after 4 weeks of acute treatment (the last MRI still showed scattered lesions) intro- duced his case to the HIV outpatient department. Clinically, he was relatively well and fully oriented and due for discharge that day. In a conversation, the patient cat- egorically refused to start the urgently recommended antiretroviral therapy. His Duesbergian physician had advised him against HIV therapy (“You can die from AZT, and the other drugs are not much better, etc”). This was why the patient would not continue the TE maintenance therapy, which had made him suffer from diarrhea (NB, probably cryptosporidiosis), skin problems (seborrhoic dermatitis, thrush), and extreme loss of weight (MAC? It was very important for him to have a break from all med- ication. In such cases, we make sure the patients sign the information sheets. Every patient is allowed to and should decide for himself (if fully cognizant and capable) – they must be fully informed about what they are doing. It is important to give the patient control: if they change their mind, they may return! In our experience, arguing with medical Duesbergians leads to nothing at all.
Metabolic profiles and body composition changes in treatment-naive HIV- infected patients treated with raltegravir 400 mg twice-daily vs Efavirenz 600 mg each bedtime combination therapy: 96-week follow-up purchase ivermectin 3 mg free shipping. Abacavir versus zidovudine combined with lamivudine and efavirenz order 3 mg ivermectin free shipping, for the treatment of antiretroviral-naive HIV-infected adults. Hepatotoxicity of nevirapine in virologically suppressed patients accord- ing to gender and CD4 cell counts. Co-formulated elvitegravir, cobicistat, emtricitabine, and tenofovir diso- proxil fumarate versus ritonavir-boosted atazanavir plus co-formulated emtricitabine and tenofovir disoproxil fumarate for initial treatment of HIV-1 infection: a randomised, double-blind, phase 3, non-inferiority trial. A case of rhabdomyolysis associated with raltegravir use. Effects of exercise training and metformin on body composition and cardiovascular indices in HIV-infected patients. Comparisons of creatinine and cystatin C for detection of kidney disease and prediction of all-cause mortality in HIV-infected women. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. Glycated Hemoglobin A1C as Screening for Diabetes Mellitus in HIV-infected Individuals. Association of osteonecrosis and osteoporosis in HIV-1-infected patients. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. Genetic and functional mitochondrial assessment of HIV-infected patients developing HAART-related hyperlactatemia. Significant effects of tipranavir on platelet aggregation and thromboxane B2 formation in vitro and in vivo. Cardiovascular risk and body-fat abnormalities in HIV-infected adults. Continuous antiretroviral therapy decreases bone mineral density. Study of Fat Redistribution and Metabolic Change in HIV Infection (FRAM). Regional adipose tissue measured by MRI over 5 years in HIV-infected and control participants indicates persistence of HIV-associated lipoatrophy. Recombinant human growth hormone to treat HIV-associated adipose redistribution syndrome: 12 week induction and 24-week maintenance therapy. Efficacy and safety of atazanavir in patients with end-stage liver disease. Surgical correction of HIV-associated facial lipoatrophy. Tenofovir-based rescue therapy for advanced liver disease in 6 patients coinfected with HIV and hepatitis B virus and receiving lamivudine. Changes in bone turnover and bone loss in HIV-infected patients changing treatment to tenofovir-emtricitabine or abacavir-lamivudine. Vitamin D3 Decreases Parathyroid Hormone in HIV-Infected Youth Being Treated With Tenofovir: A Randomized, Placebo-Controlled Trial. Management of Side Effects 297 Heiser CR, Ernst JA, Barrett JT, et al. Probiotics, soluble fiber, and L-Glutamine (GLN) reduce nelfinavir (NFV) or lopinavir/ritonavir (LPV/r) related diarrhea. Durable efficacy of tipranavir-ritonavir in combination with an optimised background regimen of antiretroviral drugs for treatment-experienced HIV-1-infected patients at 48 weeks in the Randomized Evaluation of Strategic Intervention in multi-drug resistant patients with Tipranavir (RESIST) studies: an analysis of combined data from two randomised open-label trials. Lancet 2006; 9534:466-75 Horberg M, Tang B, Towner W, et al. Impact of tenofovir on renal function in HIV-infected, antiretroviral-naive patients. A double-blinded, randomized controlled trial of zoledronate therapy for HIV-associated osteopenia and osteoporosis. Renal safety of tenofovir in HIV treatment-experienced patients. Increasing burden of liver disease in patients with HIV infection. Kim PS, Woods C, Georgoff P, Crum D, Rosenberg A, Smith M, Hadigan C. Long-term use of protease inhibitors is associated with bone mineral density loss. Toxicity of nonnucleoside analogue reverse transcriptase inhibitors. Avascular necrosis in HIV-Infected patients: A case-control study from the Aquitaine Cohort, 1997–2002, France.